Mar 27, 2026 04:03PM Moleculin Biotech (MBRX) files for 6.4M share offering by selling stockholders

Mar 23, 2026 08:33AM Moleculin reaches 45-patient milestone in pivotal leukemia trial

Feb 19, 2026 08:39AM Moleculin raises $8.3 million through warrant exercises

Feb 18, 2026 08:20AM Moleculin reports 40% response rate in leukemia drug trial

Feb 13, 2026 08:35AM Moleculin launches CEO Corner platform for investor communication

Jan 13, 2026 08:55AM Moleculin reports no cardiotoxicity in 90 Annamycin trial subjects

Jan 12, 2026 08:37AM Moleculin expects first pivotal trial data readout in Q1 2026

Dec 23, 2025 04:49PM Moleculin Biotech (MBRX) files for 2.61M share offering by selling stockholders

Dec 10, 2025 08:30AM Moleculin raises $6.5 million through warrant exercises

Dec 8, 2025 08:21AM Moleculin partners with CIC biomaGUNE for brain cancer research

Oct 29, 2025 08:35AM Moleculin receives Australian patent for Annamycin drug formulation

Sep 10, 2025 07:33AM H.C. Wainwright Reiterates Buy Rating on Moleculin Biotech (MBRX)

Aug 13, 2025 07:11PM Moleculin Biotech (MBRX) Misses Q2 EPS by 49c

Aug 6, 2025 08:42AM Moleculin presents liver cancer data for Annamycin drug candidate

Jul 30, 2025 08:35AM Moleculin receives notice for European patent on Annamycin preparation

Jul 22, 2025 08:40AM JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Jul 9, 2025 08:37AM Moleculin expands Phase 3 MIRACLE trial to Georgia

Jun 20, 2025 09:20AM Moleculin Biotech (MBRX) Prices 16.08M Share Offering at $0.37/sh

Jun 18, 2025 07:30AM Moleculin Biotech (MBRX) Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 9, 2025 06:14AM H.C. Wainwright Starts Moleculin Biotech (MBRX) at Buy

Jun 4, 2025 08:46AM Moleculin Biotech (MBRX) reports efficacy results from Annamycin phase 1B/2 trial

May 14, 2025 04:30PM Moleculin Biotech (MBRX) Tops Q1 EPS by 209c

May 12, 2025 08:40AM Moleculin Biotech (MBRX) Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 5, 2025 08:45AM Moleculin Biotech (MBRX) Granted Two New U.S. Patents

Apr 29, 2025 08:36AM Moleculin Biotech (MBRX) Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Mar 25, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Moleculin Biotech (MBRX)

Mar 6, 2025 08:32AM Moleculin Biotech (MBRX) Announces Additional Annamycin Patent Allowances

Mar 3, 2025 06:41AM Moleculin Biotech (MBRX) PT Lowered to $8 at H.C. Wainwright

Feb 25, 2025 12:35PM Moleculin Biotech (MBRX) Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 13, 2025 01:07PM Moleculin Biotech (MBRX) Announces Exercise of Warrants for $5.8M Gross Proceeds

Feb 13, 2025 09:25AM Moleculin Biotech (MBRX) Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia

Feb 11, 2025 08:40AM Moleculin Biotech (MBRX) First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Nov 14, 2024 08:16AM Moleculin Biotech (MBRX) Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Trial

Nov 12, 2024 08:03AM Moleculin Biotech (MBRX) Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia

Aug 16, 2024 08:00AM Moleculin Biotech (MBRX) Prices 2.47M Share and Warrant Offering at $2.23/sh

Aug 14, 2024 01:25PM Roth/MKM on Moleculin Biotech (MBRX): 'Undervalued Stock'

Aug 1, 2024 08:32AM Moleculin Biotech (MBRX) Plans MIRACLE Phase 3 Pivotal Trial

Jul 10, 2024 08:30AM Moleculin Biotech (MBRX) Completes End of Phase 2 Meeting with FDA for Annamycin in AML

Jun 14, 2024 08:00AM Moleculin Biotech (MBRX) Announces Additional Positive Preliminary Interim Data from AML Clinical Trial